Severe autoimmune-mediated neuropathies, such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and ...

This is particularly concerning to us as Astellas previously walked away from TSHA 120 in giant axonal neuropathy due to what appears to have been a disagreement between the two companies over the ...

BURLINGAME, CA, UNITED STATES, December 12, 2024 /EINPresswire.com/ -- According to a new report published by CoherentMI The giant axonal neuropathy (GAN) Market is ...

Giant axonal neuropathy (GAN) is a rare, autosomal recessive neurodegenerative disorder, characterized by a spectrum of symptoms and a challenging prognosis. Now, a study published recently in the New ...

It is the first time a gene therapy has been administered directly into the spinal fluid, allowing it to target the motor and sensory neuron The researchers found that with increasing dose levels ...

An investigational gene therapy for a rare neurodegenerative disease that begins in early childhood, known as giant axonal neuropathy (GAN), was well tolerated and showed signs of therapeutic benefit ...

Giant axonal neuropathy is a rare, autosomal recessive, pediatric, polysymptomatic, neurodegenerative disorder caused by biallelic loss-of-function variants in GAN, the gene encoding gigaxonin.

An investigational gene therapy for a rare neurodegenerative disease that begins in early childhood, known as giant axonal neuropathy (GAN), was well tolerated and showed signs of therapeutic ...

Opens in a new tab or window Gene therapy delivered for the first time via lumbar puncture showed promise of benefit in slowing progression of giant axonal neuropathy (GAN) in a phase I clinical ...